Clinical Trials on Advanced NSCLC

Total 6682 results

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Locally Advanced or Metastatic NSCLC

China
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Locally Advanced or Metastatic NSCLC

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
AstraZeneca

Completed

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Locally Advanced or Metastatic EGFR(+) NSCLC Patients

China
AstraZeneca

Completed

A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World. (SEQUENCE)

Locally Advanced or Metastatic EGFR Mutated NSCLC.

Taiwan
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Advanced NSCLC

China
Hatim Husain

Active, not recruiting

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC)

Advanced NSCLC

United States
Regeneron Pharmaceuticals

Recruiting

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

Advanced NSCLC

United States
Amgen

No longer available

Expanded Access of Sotorasib

Non Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLC

United States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
Arbeitsgemeinschaft medikamentoese Tumortherapie

Recruiting

Lung Cancer Registry

Lung Cancer | NSCLC Stage IV | NSCLC, Stage III | SCLC, Extensive Stage | SCLC, Limited Stage

Austria
German Cancer Research Center
University Hospital Heidelberg; National Center for Tumor Diseases, Heidelberg

Completed

POSITIVE - Study (Part III) Heidelberg (POSITIVE)

Advanced NSCLC | First Line Treatment

Germany
Seoul National University Hospital
Seoul National University Bundang Hospital; SMG-SNU Boramae Medical Center

Active, not recruiting

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Locally Advanced or Metastatic NSCLC

Korea, Republic of
AstraZeneca

Completed

Asia PDL1 Study Among NSCLC Patients (MEDI-APEX)

Locally Advanced or Metastatic NSCLC

Korea, Republic of, China, Japan
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Locally Advanced or Metastatic NSCLC

China
AstraZeneca

Completed

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours (CAURAL)

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Canada, Korea, Republic of, Taiwan
University of California, Los Angeles
University of California, San Francisco; University of California, Irvine

Active, not recruiting

UC Health Care Planning Study

Advanced Cancer | Advance Care Planning | Advance Directives

United States
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
Simcere Pharmaceutical Co., Ltd

Unknown

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Advanced NSCLC | Recurrent NSCLC

China
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
AstraZeneca

Completed

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC (IFUM)

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

Bulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
CJ Bioscience, Inc.

Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Melanoma | NSCLC | Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | HNSCC

Korea, Republic of
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

NSCLC | Advanced Cancer | Stage IV NSCLC | BRAF V600E Mutation | Stage IIIB NSCLC
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

Breast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid Tumors

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Unknown

Study of Metatinib Tromethamine Tablet

Advanced or Metastatic Gastric Cancer | Advanced or Metastatic CRC | Advanced or Metastatic Liver Cancer | Advanced or Metastatic Non Squamous NSCLC

China
Henan Cancer Hospital

Unknown

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Advanced NSCLC With EGFR Mutation

China
Daping Hospital and the Research Institute of Surgery...

Completed

Combination of Metformin With Gefitinib to Treat NSCLC (CGMT)

NSCLC | Advanced Cancer | EGFR Gene Amplification | Stage IV NSCLC | Stage IIIB NSCLC

China
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Advanced NSCLC
Qilu Hospital of Shandong University

Unknown

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Advanced Nsclc

China
Peking University Cancer Hospital & Institute

Enrolling by invitation

A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.

Locally Advanced NSCLC

China
AstraZeneca

Completed

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (GPS)

Advanced NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy

Advanced or Metastatic NSCLC

China
Mt. Sinai Medical Center, Miami
Amgen

Completed

Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Unresectable Locally Advanced NSCLC

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Palobiofarma SL
Ohio State University

Active, not recruiting

PBF-1129 in Patients With NSCLC

Locally Advanced or Metastatic NSCLC

United States
Seoul National University Hospital
AstraZeneca; Korean Cancer Study Group

Completed

Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation

Locally Advanced or Metastatic NSCLC

Korea, Republic of
Fujian Cancer Hospital

Enrolling by invitation

Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

EGFR/ ALK-negative Advanced NSCLC

China
AstraZeneca

Completed

Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy (PISCES)

Locally Advanced or Metastatic NSCLC

China
Amgen

Active, not recruiting

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

Finland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Mirati Therapeutics Inc.
Aadi Bioscience, Inc.

Active, not recruiting

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic Disease

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Untreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or Negative

China
Pfizer

Active, not recruiting

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Ovarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced Malignancies

Hungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
Maastricht Radiation Oncology
Academisch Ziekenhuis Maastricht

Terminated

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation (FDG-PET lung)

NSCLC | Lung Cancer | SCLC

Netherlands

Clinical Trials on Advanced NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations